Home › Companies › ADICET BIO INC. › 2023-2024

ADICET BIO INC. 2023-2024 Proxy Voting Records

Compiled from SEC Form N-PX filings and ADICET BIO INC.’s Form 8-K, filed 2024-06-07 (Item 5.07 on EDGAR). Page generated 02 October 2026.

8Reported items
104Asset managers
1,029Fund votes
2024-06-05Meeting date

Proxy season: 2023-2024

Explore ADICET BIO INC. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by ADICET BIO INC.

These tallies are ADICET BIO INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2024-06-07 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

ADICET BIO INC. — official shareholder meeting results, meeting held 2024-06-05
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Michael G. Kauffman, M.D., Ph.D.	41,712,563	--	--	7,432,133	12,424,510	Majority: yes
Elect Director: Andrew Sinclair, Ph.D.	38,036,535	--	--	11,108,161	12,424,510	Majority: yes
Proposal 2: Approval of an Amendment to Adicet Bio, Inc	28,859,969	20,278,299	6,428	--	12,424,510	Majority: yes
Proposal 3: Approval of an Amendment to Adicet Bio, Inc	58,940,904	2,621,988	6,314	--	12,424,510	Majority: yes
Proposal 4- Approval of an Amendment to Adicet Bio, Inc. Third Amended and Restated Certificate of Incorporation to Limit the Liability of Certain of the Company's Officers as Permitted by Delaware Law The stockholders of the Company approv	43,646,665	5,491,648	6,383	--	12,424,510	Majority: yes
Proposal 5: Non-Binding Advisory Vote on Compensation of the Company's Named Executive Officers The stockholders of the Company approved, on a non-binding advisory basis, the compensation of the Company's named executive officers	29,915,289	19,213,617	15,790	--	12,424,510	Majority: yes
Proposal 7: Ratification of Appointment of the Company's Independent Registered Public Accounting Firm The stockholders of the Company ratified the selection of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending	61,549,197	8,657	11,352	--	--	Majority: yes

Source: ADICET BIO INC., Form 8-K, filed with the SEC on 2024-06-07 — read the filing on EDGAR.

How asset managers voted at the ADICET BIO INC. 2023-2024 meeting

Each item below shows how the 104 asset managers that disclosed a ADICET BIO INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of ADICET BIO INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. To ratify, on a non-binding advisory basis, the compensation of our named executive officers.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Combines 6 wordings of this item as funds reported it.

61% Majority: yes · of votes cast

FOR 61%AGAINST 39%

FOR: 29,915,289AGAINST: 19,213,617

ADICET BIO INC.’s own tally for this item (“Proposal 5: Non-Binding Advisory Vote on Compensation of the Company's Named Executive Officers The stockholders of the Company approved, on a non-binding advisory basis, the compensation of the Company's named executive”): 29,915,289 for, 19,213,617 against, per its Form 8-K filed 2024-06-07 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 82,173,503 outstanding shares: 36% for, 23% against (60% of the company cast a for/against vote).

The 104 asset managers below cast 60% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the total votes cast at the meeting.

FOR 60%AGAINST 40%

FOR: 59.7%AGAINST: 40.3%

Largest asset managers voting on “To ratify, on a non-binding advisory basis, the compensation of our named executive officers.” at ADICET BIO INC., 2023-2024
Asset manager	For	Against	Vote
ORBIMED ADVISORS LLC	11,447,140	0	For
RA CAPITAL MANAGEMENT, L.P.	7,006,816	0	For
BALYASNY ASSET MANAGEMENT L.P.	0	5,099,436	Against
Vanguard	0	3,220,329	Against
RTW INVESTMENTS, LP	2,983,420	0	For
Carlyle Group Inc.	2,948,718	0	For
Goldman Sachs	2,672,288	247,806	For
BlackRock	11,786	2,618,043	Against
COMMODORE CAPITAL LP	0	1,374,320	Against
Fidelity	0	1,263,560	Against
Blackstone Inc.	0	1,236,453	Against
GEODE CAPITAL MANAGEMENT, LLC	0	952,058	Against
Octagon Capital Advisors LP	767,799	0	For
Woodline Partners LP	735,095	0	For
Two Sigma	0	626,550	Against
DAFNA Capital Management LLC	600,000	0	For
State Street	577,785	2,656	For
Renaissance	0	431,997	Against
Connor, Clark & Lunn Investment Management Ltd.	0	373,379	Against
Northern Trust	330,989	1,216	For
Charles Schwab	0	300,152	Against
SILVERARC CAPITAL MANAGEMENT, LLC	0	248,574	Against
MELLON INVESTMENTS Corp	0	204,366	Against
Nuveen	0	203,501	Against
TIAA	0	197,137	Against

Showing the 25 largest of 104 asset managers. See all 104 in the interactive database.

2. To ratify, on a non-binding advisory basis, the frequency of future advisory votes on the compensation of our named executive officers.

SECTION 14A SAY-ON-PAY VOTES

Combines 5 wordings of this item as funds reported it.

0.3% fund support · no official result

ONE YEAR 57%1 YEAR 43%

The 102 asset managers below cast 0.3% of the shares they voted on this item FOR (80 for, 35,072 against).

FOR: 80 (0.0%)AGAINST: 35,072 (0.1%)ONE YEAR: 28,768,982 (57.0%)1 YEAR: 21,596,267 (42.8%)THREE YEARS: 96,954 (0.2%)3 YEARS: 14,920 (0.0%)UNKNOWN: 1,184 (0.0%)

Largest asset managers voting on “To ratify, on a non-binding advisory basis, the frequency of future advisory votes on the compensation of our ” at ADICET BIO INC., 2023-2024
Asset manager	For	Against	Abstain	Withheld	Vote
ORBIMED ADVISORS LLC	0	0	0	0	1 Year
RA CAPITAL MANAGEMENT, L.P.	0	0	0	0	One Year
BALYASNY ASSET MANAGEMENT L.P.	0	0	0	0	1 Year
Vanguard	0	0	0	0	One Year
RTW INVESTMENTS, LP	0	0	0	0	One Year
Carlyle Group Inc.	0	0	0	0	One Year
Goldman Sachs	0	0	0	0	1 Year
BlackRock	0	0	0	0	One Year
COMMODORE CAPITAL LP	0	0	0	0	One Year
Fidelity	0	0	0	0	One Year
Blackstone Inc.	0	0	0	0	One Year
GEODE CAPITAL MANAGEMENT, LLC	0	0	0	0	One Year
Octagon Capital Advisors LP	0	0	0	0	1 Year
Woodline Partners LP	0	0	0	0	One Year
Two Sigma	0	0	0	0	One Year
DAFNA Capital Management LLC	0	0	0	0	1 Year
State Street	0	0	0	0	One Year
Renaissance	0	0	0	0	One Year
Connor, Clark & Lunn Investment Management Ltd.	0	0	0	0	One Year
Northern Trust	0	0	0	0	1 Year
Charles Schwab	0	0	0	0	1 Year
SILVERARC CAPITAL MANAGEMENT, LLC	0	0	0	0	One Year
MELLON INVESTMENTS Corp	0	0	0	0	One Year
Nuveen	0	0	0	0	One Year
TIAA	0	0	0	0	One Year

Showing the 25 largest of 102 asset managers. See all 102 in the interactive database.

3. To amend the Adicet Bio, Inc. Second Amended and Restated 2018 Stock Option and Incentive Plan to increase the number of shares of common stock authorized for issuance under the plan by 5,000,000 shares of common stock.

COMPENSATION

Combines 3 wordings of this item as funds reported it.

0.1% fund support · no official result

AGAINST 99.9%

The 39 asset managers below cast 0.1% of the shares they voted on this item FOR (300 for, 7,208,235 against).

FOR: 300 (0.0%)AGAINST: 7,208,235 (100.0%)

Largest asset managers voting on “To amend the Adicet Bio, Inc. Second Amended and Restated 2018 Stock Option and Incentive Plan to increase the” at ADICET BIO INC., 2023-2024
Asset manager	Against	Vote
Vanguard	3,187,084	Against
BlackRock	1,512,659	Against
Fidelity	1,063,513	Against
TIAA	197,137	Against
Goldman Sachs	183,375	Against
Charles Schwab	150,076	Against
ETF Series Solutions	140,011	Against
BRIDGEWAY FUNDS INC	129,800	Against
TARGET PORTFOLIO TRUST	103,400	Against
QUANTITATIVE MASTER SERIES LLC	99,541	Against
Equitable	88,344	Against
American Century	58,437	Against
Dimensional	36,397	Against
Lincoln Financial	30,929	Against
Pacific Life	23,780	Against
Bridge Builder Trust	21,312	Against
Nationwide	20,746	Against
Voya	20,267	Against
Northern Trust	19,898	Against
Managed Portfolio Series	18,074	Against
John Hancock	16,055	Against
Jackson National	14,920	Against
Principal Exchange-Traded Funds	12,488	Against
HC CAPITAL TRUST	10,211	Against
Blackstone Alternative Investment Funds	7,842	Against

Showing the 25 largest of 39 asset managers. See all 39 in the interactive database.

4. To elect two class III directors, to serve for a three-year term ending at the Annual Meeting of Stockholders to be held in 2027: Andrew Sinclair, Ph.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 2 wordings of this item as funds reported it.

77% Majority: yes · of votes cast

FOR 77%WITHHELD 23%

FOR: 38,036,535WITHHELD: 11,108,161

ADICET BIO INC.’s own tally for this item (“Elect Director: Andrew Sinclair, Ph.D.”): 38,036,535 for, 11,108,161 withheld, per its Form 8-K filed 2024-06-07 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 82,173,503 outstanding shares: 46.3% for, 14% withheld (60% of the company cast a for/withheld vote).

The 38 asset managers below cast 100% of the shares they voted on this item FOR (3,460,690 for, 0 against).

FOR 48.0%ABSTAIN 52.0%

FOR: 3,460,690 (48.0%)ABSTAIN: 3,747,545 (52.0%)

Largest asset managers voting on “To elect two class III directors, to serve for a three-year term ending at the Annual Meeting of Stockholders ” at ADICET BIO INC., 2023-2024
Asset manager	For	Abstain	Vote
Vanguard	3,187,084	0	For
BlackRock	0	1,512,659	Abstain
Fidelity	0	1,063,513	Abstain
TIAA	0	197,137	Abstain
Goldman Sachs	0	183,375	Abstain
Charles Schwab	150,076	0	For
ETF Series Solutions	0	140,011	Abstain
BRIDGEWAY FUNDS INC	0	129,800	Abstain
TARGET PORTFOLIO TRUST	103,400	0	For
QUANTITATIVE MASTER SERIES LLC	0	99,541	Abstain
Equitable	0	88,344	Abstain
American Century	0	58,437	Abstain
Dimensional	0	36,397	Abstain
Lincoln Financial	0	30,929	Abstain
Pacific Life	0	23,780	Abstain
Bridge Builder Trust	0	21,312	Abstain
Nationwide	0	20,746	Abstain
Voya	0	20,267	Abstain
Northern Trust	19,898	0	For
Managed Portfolio Series	0	18,074	Abstain
John Hancock	0	16,055	Abstain
Jackson National	0	14,920	Abstain
Principal Exchange-Traded Funds	0	12,488	Abstain
HC CAPITAL TRUST	0	10,211	Abstain
Blackstone Alternative Investment Funds	0	7,842	Abstain

Showing the 25 largest of 38 asset managers. See all 38 in the interactive database.

5. To elect two class III directors, to serve for a three-year term ending at the Annual Meeting of Stockholders to be held in 2027: Michael G. Kauffman, M.D., Ph.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

85% Majority: yes · of votes cast

FOR 85%WITHHELD 15%

FOR: 41,712,563WITHHELD: 7,432,133

ADICET BIO INC.’s own tally for this item (“Elect Director: Michael G. Kauffman, M.D., Ph.D.”): 41,712,563 for, 7,432,133 withheld, per its Form 8-K filed 2024-06-07 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 82,173,503 outstanding shares: 50.8% for, 9% withheld (60% of the company cast a for/withheld vote).

The 38 asset managers below cast 100% of the shares they voted on this item FOR (6,081,247 for, 0 against).

FOR 84%ABSTAIN 16%

FOR: 6,081,247 (84.4%)ABSTAIN: 1,126,988 (15.6%)

Largest asset managers voting on “To elect two class III directors, to serve for a three-year term ending at the Annual Meeting of Stockholders ” at ADICET BIO INC., 2023-2024
Asset manager	For	Abstain	Vote
Vanguard	3,187,084	0	For
BlackRock	1,512,659	0	For
Fidelity	867,606	195,907	For
TIAA	0	197,137	Abstain
Goldman Sachs	0	183,375	Abstain
Charles Schwab	150,076	0	For
ETF Series Solutions	0	140,011	Abstain
BRIDGEWAY FUNDS INC	0	129,800	Abstain
TARGET PORTFOLIO TRUST	103,400	0	For
QUANTITATIVE MASTER SERIES LLC	99,541	0	For
Equitable	51,604	36,740	For
American Century	0	58,437	Abstain
Dimensional	0	36,397	Abstain
Lincoln Financial	0	30,929	Abstain
Pacific Life	23,780	0	For
Bridge Builder Trust	21,312	0	For
Nationwide	0	20,746	Abstain
Voya	20,267	0	For
Northern Trust	19,898	0	For
Managed Portfolio Series	18,074	0	For
John Hancock	0	16,055	Abstain
Jackson National	0	14,920	Abstain
Principal Exchange-Traded Funds	0	12,488	Abstain
HC CAPITAL TRUST	0	10,211	Abstain
Blackstone Alternative Investment Funds	0	7,842	Abstain

Showing the 25 largest of 38 asset managers. See all 38 in the interactive database.

6. To amend the Third Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 150,000,000 to 300,000,000.

CAPITAL STRUCTURE

Combines 2 wordings of this item as funds reported it.

98% fund support · no official result

FOR 98%

The 38 asset managers below cast 98% of the shares they voted on this item FOR (7,094,624 for, 113,611 against).

FOR: 7,094,624 (98.4%)AGAINST: 113,611 (1.6%)

Largest asset managers voting on “To amend the Third Amended and Restated Certificate of Incorporation to increase the number of authorized shar” at ADICET BIO INC., 2023-2024
Asset manager	For	Against	Vote
Vanguard	3,187,084	0	For
BlackRock	1,512,659	0	For
Fidelity	1,063,513	0	For
TIAA	197,137	0	For
Goldman Sachs	183,375	0	For
Charles Schwab	150,076	0	For
ETF Series Solutions	140,011	0	For
BRIDGEWAY FUNDS INC	129,800	0	For
TARGET PORTFOLIO TRUST	0	103,400	Against
QUANTITATIVE MASTER SERIES LLC	99,541	0	For
Equitable	88,344	0	For
American Century	58,437	0	For
Dimensional	36,397	0	For
Lincoln Financial	30,929	0	For
Pacific Life	23,780	0	For
Bridge Builder Trust	21,312	0	For
Nationwide	20,746	0	For
Voya	20,267	0	For
Northern Trust	19,898	0	For
Managed Portfolio Series	18,074	0	For
John Hancock	16,055	0	For
Jackson National	14,920	0	For
Principal Exchange-Traded Funds	12,488	0	For
HC CAPITAL TRUST	0	10,211	Against
Blackstone Alternative Investment Funds	7,842	0	For

Showing the 25 largest of 38 asset managers. See all 38 in the interactive database.

7. To amend the Third Amended and Restated Certificate of Incorporation to limit the liability of certain of the Company's officers as permitted by Delaware law.

CORPORATE GOVERNANCEMajority of the votes cast: yes

Combines 2 wordings of this item as funds reported it.

89% Majority: yes · of votes cast

FOR 89%11%

FOR: 43,646,665AGAINST: 5,491,648

ADICET BIO INC.’s own tally for this item (“Proposal 4- Approval of an Amendment to Adicet Bio, Inc. Third Amended and Restated Certificate of Incorporation to Limit the Liability of Certain of the Company's Officers as Permitted by Delaware Law The stockholders o”): 43,646,665 for, 5,491,648 against, per its Form 8-K filed 2024-06-07 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 82,173,503 outstanding shares: 53.1% for, 7% against (60% of the company cast a for/against vote).

The 38 asset managers below cast 99.5% of the shares they voted on this item FOR (7,175,217 for, 33,018 against).

FOR 99.5%

FOR: 7,175,217 (99.5%)AGAINST: 33,018 (0.5%)

Largest asset managers voting on “To amend the Third Amended and Restated Certificate of Incorporation to limit the liability of certain of the ” at ADICET BIO INC., 2023-2024
Asset manager	For	Against	Vote
Vanguard	3,187,084	0	For
BlackRock	1,512,659	0	For
Fidelity	1,063,513	0	For
TIAA	197,137	0	For
Goldman Sachs	183,375	0	For
Charles Schwab	150,076	0	For
ETF Series Solutions	140,011	0	For
BRIDGEWAY FUNDS INC	129,800	0	For
TARGET PORTFOLIO TRUST	103,400	0	For
QUANTITATIVE MASTER SERIES LLC	99,541	0	For
Equitable	88,344	0	For
American Century	58,437	0	For
Dimensional	36,397	0	For
Lincoln Financial	30,929	0	For
Pacific Life	23,780	0	For
Bridge Builder Trust	21,312	0	For
Nationwide	20,746	0	For
Voya	20,267	0	For
Northern Trust	19,898	0	For
Managed Portfolio Series	0	18,074	Against
John Hancock	16,055	0	For
Jackson National	14,920	0	For
Principal Exchange-Traded Funds	12,488	0	For
HC CAPITAL TRUST	0	10,211	Against
Blackstone Alternative Investment Funds	7,842	0	For

Showing the 25 largest of 38 asset managers. See all 38 in the interactive database.

8. To ratify the appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.

AUDIT-RELATEDMajority of the votes cast: yes

Combines 2 wordings of this item as funds reported it.

99.9% Majority: yes · of votes cast

FOR 99.9%

FOR: 61,549,197AGAINST: 8,657

ADICET BIO INC.’s own tally for this item (“Proposal 7: Ratification of Appointment of the Company's Independent Registered Public Accounting Firm The stockholders of the Company ratified the selection of KPMG LLP as the Company's independent registered public acc”): 61,549,197 for, 8,657 against, per its Form 8-K filed 2024-06-07 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 82,173,503 outstanding shares: 75% for, 0.1% against (75% of the company cast a for/against vote).

The 38 asset managers below cast 100% of the shares they voted on this item FOR (7,208,235 for, 0 against).

FOR 100%

FOR: 7,208,235 (100.0%)

Largest asset managers voting on “To ratify the appointment of KPMG LLP as the Company's independent registered public accounting firm for the f” at ADICET BIO INC., 2023-2024
Asset manager	For	Vote
Vanguard	3,187,084	For
BlackRock	1,512,659	For
Fidelity	1,063,513	For
TIAA	197,137	For
Goldman Sachs	183,375	For
Charles Schwab	150,076	For
ETF Series Solutions	140,011	For
BRIDGEWAY FUNDS INC	129,800	For
TARGET PORTFOLIO TRUST	103,400	For
QUANTITATIVE MASTER SERIES LLC	99,541	For
Equitable	88,344	For
American Century	58,437	For
Dimensional	36,397	For
Lincoln Financial	30,929	For
Pacific Life	23,780	For
Bridge Builder Trust	21,312	For
Nationwide	20,746	For
Voya	20,267	For
Northern Trust	19,898	For
Managed Portfolio Series	18,074	For
John Hancock	16,055	For
Jackson National	14,920	For
Principal Exchange-Traded Funds	12,488	For
HC CAPITAL TRUST	10,211	For
Blackstone Alternative Investment Funds	7,842	For

Showing the 25 largest of 38 asset managers. See all 38 in the interactive database.

Largest ADICET BIO INC. shareholders voting in 2023-2024

Ranked by the number of ADICET BIO INC. shares each manager voted on the most widely held ballot item of the 2023-2024 meeting, shown as a share of the 82,173,503 shares outstanding at the time of that meeting.

Top ADICET BIO INC. shareholders by shares voted, 2023-2024
#	Asset manager	% of shares outstanding
1	ORBIMED ADVISORS LLC	13.93%
2	RA CAPITAL MANAGEMENT, L.P.	8.53%
3	BALYASNY ASSET MANAGEMENT L.P.	6.21%
4	Vanguard	3.92%
5	RTW INVESTMENTS, LP	3.63%
6	Carlyle Group Inc.	3.59%
7	Goldman Sachs	3.55%
8	BlackRock	3.20%
9	COMMODORE CAPITAL LP	1.67%
10	Fidelity	1.54%

Reported ADICET BIO INC. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

ADICET BIO INC. beneficial owners on record for the 2023-2024 proxy season
Holder	% outstanding	Disclosure
Carl L. Gordon, Ph.D.	14.05%	DEF14A
Entities affiliated with OrbiMed	14.05%	DEF14A
RA Capital Healthcare Fund, L.P.	9.37%	DEF14A
Tang Capital Partners, LP	7.18%	DEF14A
Commodore Capital Master LP	5.17%	DEF14A
RTW Investments, LP	5.03%	DEF14A
Millennium Management	5.00%	13F
Goldman Sachs	4.57%	13F
Vanguard Group	3.98%	13F
Cowen Financial Products LLC	3.30%	13G

Percentages above are of 82,173,503 shares outstanding, as reported by ADICET BIO INC. on its Form 10-Q dated 2024-05-10 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from ADICET BIO INC.’s 10-Q dated 2024-05-10. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At ADICET BIO INC.'s shareholder meeting held 2024-06-05, in the 2023-2024 proxy season, 104 asset managers reported how they voted in their SEC Form N-PX filings, covering 1,029 separate fund positions. Their filings are grouped here into 8 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — To ratify, on a non-binding advisory basis, the compensation of our named executive officers. — FOR was 61% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: ADICET BIO INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2024-06-07.

ADICET BIO INC. proxy season coverage: 2023-2024 (this page).